Drug Profile

STP 165G

Alternative Names: STP-165G

Latest Information Update: 03 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sirnaomics
Class Amides; Amino sugars; Antihypertensives; Drug conjugates; Small interfering RNA
Mechanism of Action Angiotensinogen expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

21 Aug 2022 STP 165G is available for licensing as of 21 Aug 2022. https://sirnaomics.com/en/partnership/
21 Aug 2022 Sirnaomics has 119 patents pending applications in multiple countries for siRNAs and mRNa therapeutics(Sirnaomics website, August 2022)
21 Aug 2022 Sirnaomics has patent protection in China, Europe and USA for siRNAs and mRNa therapeutics (Sirnaomics website, August 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com